Necrotizing vasculitis
MONDO:0800113A type of vasculitis that is comprised of vasculitides that present with necrosis.
Also known as: systemic vasculitis
140 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Steroid showdown: can a tiny daily dose keep a rare disease at bay?
Disease control CompletedThis study looked at 159 people with granulomatosis with polyangiitis (GPA), a rare disease that causes inflammation of blood vessels. Participants were randomly assigned to either stay on a low 5 mg daily dose of prednisone or slowly stop it over six months. The goal was to see …
Phase: PHASE3 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New combo therapy aims to tame rare blood vessel disease
Disease control CompletedThis study tested whether adding rituximab to standard steroid treatment helps adults with IgA vasculitis (a disease causing inflamed blood vessels) achieve remission without needing steroids long-term. 75 participants with new or relapsing disease were randomly assigned to recei…
Phase: PHASE3 • Sponsor: Hopital Foch • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Real-World data shows mepolizumab may keep rare vasculitis in check Long-Term
Disease control CompletedThis study followed 591 adults with eosinophilic granulomatosis with polyangiitis (EGPA) across Europe to see how well mepolizumab 300mg every 4 weeks works over the long term in everyday medical practice. Researchers looked at disease control, lung function, and safety by review…
Sponsor: European EGPA Study Group • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Small study tests rituximab against rare vessel disease
Disease control CompletedThis study tested whether the drug rituximab, given with steroids, works better than steroids alone for people with a rare disease called microscopic polyangiitis that inflames small blood vessels. Only 8 patients took part, and the goal was to see if the combination could preven…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New study tracks Nucala's Long-Term impact on rare inflammatory disease
Disease control CompletedThis study followed about 300 people with EGPA (a rare disease causing inflammation in blood vessels) who were treated with Nucala injections for up to 2 years. Researchers monitored side effects, how well the drug controlled symptoms, and how long it took for the disease to flar…
Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Real-World FASENRA study completed in korea: safety under the microscope
Disease control CompletedThis completed study looked at the safety and effectiveness of FASENRA (benralizumab) in 51 Korean adults with severe eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA). Researchers tracked side effects and how well the drug controlled symptoms during rou…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug MT-2990 tested in rare blood vessel disease
Disease control CompletedThis early study looked at a new drug, MT-2990, in 5 people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. The goal was to see if the drug is safe and how it affects disease activity. Researchers measured changes in symptoms, imagin…
Phase: PHASE1 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for EGPA: rituximab shows promise in major trial
Disease control CompletedThis study tested whether the drug rituximab can help people with a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA) achieve remission better than standard treatments. 107 adults with active EGPA were randomly assigned to receive either rituximab or conven…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Cheaper rituximab versions just as safe and effective for rare vasculitis?
Disease control CompletedThis study looked at 201 Canadian patients with ANCA-associated vasculitis to see if cheaper biosimilar versions of rituximab work as well as the original drug. Researchers compared disease control, side effects, and how long it took to get insurance approval for treatment. The g…
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Statin trial targets hidden heart risk in vasculitis patients
Disease control CompletedThis study tested whether rosuvastatin, a common cholesterol-lowering drug, could reduce early signs of artery hardening in 121 people with ANCA-associated vasculitis. Participants were in remission and received either rosuvastatin or a placebo for up to 2 years. The goal was to …
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Can a Double-Dose vaccine strategy shield vulnerable vasculitis patients?
Disease control CompletedThis study tested whether giving a stronger pneumococcal vaccine schedule (either two doses close together or a single larger dose) followed by a standard booster could improve immune protection in 96 adults with ANCA-associated vasculitis who are also receiving rituximab therapy…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Rituximab vs. azathioprine: which drug better prevents EGPA flares?
Disease control CompletedThis study tested whether rituximab (given as an infusion every 6 months) is better than azathioprine (daily pills) at keeping eosinophilic granulomatosis with polyangiitis (EGPA) in remission. 98 adults with newly diagnosed or relapsing EGPA who had already achieved remission to…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Rituximab shows promise in preventing vasculitis relapses
Disease control CompletedThis study tested whether rituximab, a targeted antibody therapy, is better than azathioprine, a standard immune-suppressing drug, at preventing relapses in people with ANCA-associated vasculitis. 117 patients who had achieved remission were randomly assigned to receive either ri…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Can extra rituximab keep vasculitis at bay?
Disease control CompletedThis study looked at whether giving rituximab for 46 months instead of the usual 18 months can better prevent relapses of ANCA-associated vasculitis, a rare autoimmune disease that causes blood vessel inflammation. 97 patients who were already in remission after initial rituximab…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New hope for rare lung scarring? small trial tests pirfenidone
Disease control CompletedThis small pilot study looked at whether the drug pirfenidone is safe and effective for people with a specific type of lung scarring (pulmonary fibrosis) linked to MPO antibodies or vasculitis. Seven adults took the drug for a year, and researchers measured changes in lung functi…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New combo therapy aims to tame rare blood vessel disease
Disease control CompletedThis study tested whether adding azathioprine to standard corticosteroid treatment helps people with certain types of vasculitis (blood vessel inflammation) achieve remission and avoid relapses. 114 newly diagnosed patients without poor prognosis factors took part. The goal was t…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 26, 2026 16:48 UTC
-
Smart dosing of rituximab may keep rare blood vessel disease at bay
Disease control CompletedThis study tested two ways of giving rituximab to people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. All 166 participants were in remission and received rituximab either on a fixed schedule or only when certain blood markers (ANC…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 26, 2026 13:48 UTC
-
Can a drug shrink nasal polyps in rare disease patients?
Symptom relief CompletedThis study looked at 52 adults with EGPA (a rare inflammatory disease) and severe chronic sinusitis with nasal polyps. They received mepolizumab 300 mg every 4 weeks. The goal was to see if the drug reduces polyp size and improves symptoms like nasal congestion and sense of smell…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Could a tiny dose of naltrexone ease vasculitis symptoms?
Symptom relief CompletedThis study tested whether a low dose (4.5 mg) of naltrexone, a drug already used for alcoholism, can improve physical health and quality of life in people with vasculitis. Sixty participants took either the drug or a placebo daily for six weeks. The goal was to see if the drug le…
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
A blood clue to a rare vessel disease?
Knowledge-focused CompletedThis study looks at whether a protein in the blood, called soluble CD95 ligand, plays a role in ANCA-associated vasculitis, a rare group of diseases that cause inflammation of blood vessels. Researchers will collect blood and urine samples from 48 adults with the condition and tr…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Aug 18, 2026 06:00 UTC
-
PET scans could revolutionize monitoring of rare inflammatory disease
Knowledge-focused CompletedThis study explores whether a special type of PET/CT scan, using a radioactive tracer called 18F-FDG, can accurately measure disease activity in people with granulomatosis with polyangiitis (GPA), a rare condition that causes inflammation of blood vessels. Researchers will compar…
Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Massive study reveals hidden dangers of common steroid treatments
Knowledge-focused CompletedThis completed study looked at over 107,000 patients in Germany to understand the long-term side effects of systemic steroids (corticosteroids) used for conditions like asthma, COPD, and arthritis. Researchers compared patients who took steroids with those who did not, tracking r…
Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists probe immune cell clues in rare disease
Knowledge-focused CompletedThis study looked at immune cells from 138 people with Wegener's granulomatosis, a rare disease causing inflammation of blood vessels. Researchers measured levels of a protein called DAP12 in different immune cells to understand how the disease works. No new treatment was tested;…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
COVID-19's hidden toll on autoimmune patients revealed
Knowledge-focused CompletedThis study followed 293 people with autoimmune diseases and healthy volunteers to see how COVID-19 infection or vaccination affects their immune system, inflammation, and blood vessels. Participants were grouped based on their COVID-19 history and had up to 5 visits over 12-18 mo…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Blood filter showdown: which method clears harmful antibodies faster?
Knowledge-focused CompletedThis study compares two blood-filtering techniques—plasma exchange and immunoadsorption—in 40 patients with severe kidney failure caused by ANCA vasculitis or Goodpasture disease. The goal is to see which method removes disease-causing antibodies more quickly. Results may help do…
Phase: NA • Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Study reveals gaps in Follow-Up care for kids with rheumatoid purpura
Knowledge-focused CompletedThis study observed 66 children diagnosed with rheumatoid purpura in three French hospital emergency rooms. Researchers tracked how well doctors followed official care guidelines and surveyed family doctors about their knowledge of the condition. The goal was to identify obstacle…
Sponsor: Groupe Hospitalier de la Region de Mulhouse et Sud Alsace • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Immune cell study sheds light on childhood disease
Knowledge-focused CompletedThis study examined blood samples from 100 children with Henoch Schönlein Purpura (HSP) and a control group to see if regulatory T cells (Tregs) are missing or not working properly. The goal was to learn more about the disease, not to test a new treatment. Researchers measured Tr…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Scientists probe immune cells to unlock vasculitis mysteries
Knowledge-focused CompletedThis study looked at how certain immune cells, called neutrophils, behave in people with granulomatosis with polyangiitis (GPA), a rare blood vessel inflammation disease. Researchers collected blood samples from 93 participants, including patients with GPA and other related condi…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:35 UTC